Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell-cytokine-induced killer cell vaccine
- Development stage
- Unknown
- Lead developer
- Lanzhou University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal
01
Overview
A cellular immunotherapy consisting of autologous dendritic cells (DCs) and cytokine-induced killer (CIK) cells. DCs are typically pulsed with tumor-associated antigens (such as those from gastric cancer cell lysates) to enhance antigen presentation and prime T-cell responses. CIK cells are a heterogeneous population of effector T cells (predominantly CD3+CD56+) generated by the ex vivo expansion of peripheral blood mononuclear cells in the presence of cytokines like IFN-gamma, IL-2, and anti-CD3 antibodies. This combination therapy leverages the potent antigen-presenting capabilities of DCs and the non-MHC-restricted cytotoxic activity of CIK cells to target and eliminate residual tumor cells. Lanzhou University has been a key developer investigating this vaccine as an adjuvant treatment for gastric cancer to improve survival outcomes and reduce recurrence.
- Other names
- DC-CIK vaccineDC-CIK therapyDC-CIK immunotherapydendritic cell-cytokine-induced killer cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)γδ TCR (T-cell receptor)pMHC (Peptide-MHC complex family)MHC I (MHC class I})
Beyond the preview
Go deeper on dendritic cell-cytokine-induced killer cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell-cytokine-induced killer cell vaccine.